Mrinal M Gounder

Mrinal M Gounder

UNVERIFIED PROFILE

Are you Mrinal M Gounder?   Register this Author

Register author
Mrinal M Gounder

Mrinal M Gounder

Publications by authors named "Mrinal M Gounder"

Are you Mrinal M Gounder?   Register this Author

35Publications

1309Reads

36Profile Views

Treatment of dedifferentiated chordoma: a retrospective study from a large volume cancer center.

J Neurooncol 2019 Sep 23;144(2):369-376. Epub 2019 Jul 23.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 22, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03239-3DOI Listing
September 2019

Sorafenib for Advanced and Refractory Desmoid Tumors.

N Engl J Med 2018 12;379(25):2417-2428

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center (M.M.G., W.D.T., N.H., N.P.A., R.A.L., Y.M., R.Y.) and Columbia University Vagellos College of Physicians and Surgeons and New York Presbyterian Hospital (L.H.S., G.K.S.), New York, and Northwell Cancer Institute and Cold Spring Harbor Laboratory, Lake Success (R.G.M.) - all in New York; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN (M.R.M.); Washington University School of Medicine, St. Louis (B.A.V.T.); M.D. Anderson Cancer Center, University of Texas, Houston (V.R.); Mayo Clinic in Florida, Jacksonville (S.A.); Yale University, New Haven, CT (H.A.D.); University Health Network Princess Margaret Cancer Centre, Toronto (A.A.G.); University of Iowa-Holden Comprehensive Cancer Center, Iowa City (M.M.M.); University of Alabama at Birmingham Cancer Center, Birmingham (R.M.C.); Fox Chase Cancer Center, Philadelphia (S.M.); Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC (M.J.P.); Duke Cancer Institute, Duke University Medical Center, Durham (R.F.R.), and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill (E.B.) - both in North Carolina; Dayton National Cancer Institute Community Oncology Research Program, Dayton, OH (T.S.); National Cancer Institute, Bethesda, MD (J.J.W.); and the Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ (A.C.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447029PMC
December 2018

Reply to E. Younger et al.

J Clin Oncol 2018 06 18;36(16):1643-1644. Epub 2018 Apr 18.

Thomas M. Atkinson, Memorial Sloan Kettering Cancer Center, New York, NY; and Mrinal M. Gounder, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.0478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362829PMC
June 2018

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.

N Engl J Med 2018 05;378(20):1945-1947

Memorial Sloan Kettering Cancer Center, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1511490DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062005PMC
May 2018

Locally Aggressive Connective Tissue Tumors.

J Clin Oncol 2018 01 8;36(2):202-209. Epub 2017 Dec 8.

Mrinal M. Gounder and William D. Tap, Memorial Sloan Kettering Cancer Center and Weil Cornell Medical School, New York, NY; and David M. Thomas, Garvan Institute of Medical Research, Darlinghurst, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.8482DOI Listing
January 2018

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 08;23(8):1004

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0817-1004cDOI Listing
August 2017

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 Jun 8;23(6):703-713. Epub 2017 May 8.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nm.4333
Publisher Site
http://dx.doi.org/10.1038/nm.4333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461196PMC
June 2017

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

J Clin Oncol 2016 09 25;34(26):3166-74. Epub 2016 Jul 25.

Mrinal M. Gounder, William D. Tap, Mark A. Dickson, Mary Louise Keohan, Sandra P. D'Angelo, Mercedes Condy, Lanier Tanner, Joseph P. Erinjeri, and Francis H. Jasmine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Alona Zer, Samer Salah, Abha A. Gupta, Herbert H. Loong, Stephanie Baker, Kjirsten Nyquist-Schultz, and Albiruni Ryan Abdul Razak, Princess Margaret Cancer Center, Toronto, Ontario, Canada; and Sharon Friedlander, Robert Carlson, Thaddeus J. Unger, Jean-Richard Saint-Martin, Tami Rashal, Joel Ellis, Michael Kauffman, and Sharon Shacham, Karyopharm Therapeutics, Newton, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.6346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321073PMC
September 2016

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.

Clin Cancer Res 2016 Feb 31;22(3):553-9. Epub 2015 Aug 31.

Weill Cornell Medical College, New York, New York. Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0339DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819316PMC
February 2016

Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory?".

Authors:
Mrinal M Gounder

Cancer 2015 Nov 8;121(22):3933-7. Epub 2015 Sep 8.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29562DOI Listing
November 2015

Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

J Clin Oncol 2015 Oct 17;33(28):3186-92. Epub 2015 Aug 17.

Mrinal M. Gounder, Armando J. Sanchez, and Lisa M. DeAngelis, Memorial Sloan-Kettering Cancer Center and Weil Cornell Medical School, New York, NY; Lakshmi Nayak and Patrick Y. Wen, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School; Alona Muzikansky, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Solmaz Sahebjam, Moffitt Cancer Center, University of South Florida, Tampa, FL; Serena Desideri, Xiaobu Ye, and Stuart Grossman, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore; S. Percy Ivy, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; and Michael Prados, University of California at San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.1525DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857195PMC
October 2015

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.

Oncotarget 2015 Aug;6(22):19316-27

Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662493PMC
http://dx.doi.org/10.18632/oncotarget.2909DOI Listing
August 2015

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.

J Pharm Biomed Anal 2014 Nov 12;100:199-204. Epub 2014 Aug 12.

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15213, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07317085140037
Publisher Site
http://dx.doi.org/10.1016/j.jpba.2014.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179924PMC
November 2014

Reply to M. Voskoboynik et al.

J Clin Oncol 2014 Oct 28;32(28):3199-200. Epub 2014 Jul 28.

Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.5762DOI Listing
October 2014

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

J Clin Oncol 2014 Feb 13;32(6):519-26. Epub 2014 Jan 13.

David M. Hyman, Anne A. Eaton, Mrinal M. Gounder, Erika G. Pamer, Martee L. Hensley, David R. Spriggs, and Alexia Iasonos, Memorial Sloan-Kettering Cancer Center; David M. Hyman, Mrinal M. Gounder, Martee L. Hensley, David R. Spriggs, and Alexia Iasonos, Weill Cornell Medical College, New York, NY; and Gary L. Smith and Percy Ivy, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.8808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918535PMC
February 2014

Moving forward one Notch at a time.

J Clin Oncol 2012 Jul 7;30(19):2291-3. Epub 2012 May 7.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.42.3277
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.42.3277DOI Listing
July 2012

Activity of Sorafenib against desmoid tumor/deep fibromatosis.

Clin Cancer Res 2011 Jun 29;17(12):4082-90. Epub 2011 Mar 29.

Departments of Medicine, Radiology, Pathology, and Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-3322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981PMC
June 2011

Inclusion of patients with brain metastases in phase I trials: an unmet need.

Clin Cancer Res 2011 Jun 28;17(12):3855-7. Epub 2011 Apr 28.

Developmental Therapeutics Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-0759DOI Listing
June 2011

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.

Cancer Chemother Pharmacol 2011 Jan 30;67 Suppl 1:S25-43. Epub 2010 Nov 30.

Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1526-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275340PMC
January 2011